Sodium aurothiomalate

Thông tin thuốc gốc
Chỉ định và Liều dùng
Progressive juvenile idiopathic arthritis
Child: 1 mg/kg weekly. Max: 50 mg weekly. Calculated initial weekly dose may be preceded by a smaller test dose such as 1/10 or 1/5 of the full dose for 2-3 weeks. Continue weekly doses until signs of remission occur then increase dosage intervals to 2 weeks. With full remission, dosage interval may be increased gradually to 4 weeks. If no improvement after 20 weeks, dose may be raised slightly or another antirheumatic drug may be tried.

Active progressive rheumatoid arthritis
Adult: Initially, 10 mg in the 1st week as test dose, followed by 50 mg weekly until signs of remission occur. Dosage interval is then increased to 2 weeks until full remission, then increased gradually to 4-6 weeks. May continue for up to 5 years after complete remission. Discontinue if no major improvement is seen after a total of 1 g (excluding test dose) has been given, or alternatively, in the absence of toxicity, 100 mg may be given weekly for further 6 weeks. Discontinue if there is no sign of remission.
Suy thận
Severe: Contraindicated.
Suy gan
Severe: Contraindicated.
Chống chỉ định
Exfoliative dermatitis, SLE, necrotising enterocolitis, pulmonary fibrosis. History of haematological disorders, toxicity to heavy metals. Severely debilitated patients. Severe renal or hepatic impairment. Concomitant use w/ antimalarials, immunosuppressive agents, penicillamine or phenylbutazone.
Thận trọng
Patient w/ DM, heart failure, marked HTN, compromised cerebral or CV circulation. History of urticaria, eczema or colitis. Mild to moderate renal or hepatic impairment. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Pruritus, stomatitis, erythema multiforme, urticaria, eczema, seborrhoeic dermatitis, lichenoid eruptions, alopecia, exfoliative dermatitis, glossitis, pharyngitis, vaginitis, photosensitivity reactions, chrysiasis, eosinophilia, thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia, proteinuria, haematuria, nephrosis, pulmonary fibrosis, dyspnoea, toxic hepatitis, cholestatic jaundice, peripheral neuritis, encephalitis, psychoses, fever, weakness, flushing, palpitations, syncope. Rarely, iritis, corneal ulcers, golds deposit in the eye.
Potentially Fatal: Rarely, ulcerative colitis.
Chỉ số theo dõi
Perform CBC w/ differential, platelet count, urinalysis for protein and LFT prior to initiation of therapy. Skin and oral mucosa inspection.
Tương tác
Drug Interaction: May increase risk of aspirin-induced liver damage. Increased risk of severe anaphylactoid reaction when used w/ ACE inhibitors.
Potentially Fatal: Increased risk of blood dyscrasias and other severe adverse effects (e.g. proteinuria) when used concomitantly w/ myelossupressive agents, phenylbutazone, penicillamine and antimalarials.
Ảnh hưởng đến kết quả xét nghiệm
May interfere w/ serum protein-bound iodine measurement by chloric acid digestion method.
Tác dụng
Description: Sodium aurothiomalate is a disease-modifying antirheumatic drug, used in patients whose symptoms are unresponsive to or inadequately controlled by NSAID alone. The exact mechanism of action has not been established, but its predominant action appears to be a suppressive effect on the synovitis of active rheumatoid disease. It may act by altering function of other enzymes by inhibiting lysosomal enzymes, by suppressing phagocytic activity of macrophages and polymorphonuclear leukocytes, or by altering immune response.
Onset: Delayed; may require up to 3 mth.
Absorption: Readily absorbed after IM inj. Time to peak serum concentration: 4-6 hr.
Distribution: Widely distributed in body tissues and fluids. Crosses placenta and enters breast milk. Plasma protein binding: 85-95%.
Excretion: Via urine (60%-90%) and faeces (10%-40%). Elimination half-life: Approx 5-6 days.
Đặc tính

Chemical Structure Image
Sodium aurothiomalate

Source: National Center for Biotechnology Information. PubChem Database. Sodium aurothiomalate, CID=22318, (accessed on Jan. 23, 2020)

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Thuốc chống thấp khớp có cải thiện bệnh trạng
Phân loại ATC
M01CB01 - sodium aurothiomalate ; Belongs to the class of gold preparations of antirheumatic agents.
Tài liệu tham khảo
Anon. Gold Sodium Thiomalate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 12/07/2016.

Buckingham R (ed). Sodium aurothiomalate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 12/07/2016.

Joint Formulary Committee. Sodium aurothiomalate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 12/07/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Aurothioglucose, Gold Sodium Thiomalate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 12/07/2016.

Myochrysine Injection (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 12/07/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Sodium aurothiomalate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in